Azenta, INC

Azenta, Inc. has formalized the compensation for its Interim President and CEO, Dr. Martin D. Madaus, and granted significant retention awards to other named executive officers.

Azenta, Inc. announced the full repayment of a $35 million vendor loan related to the sale of B Medical Systems, receiving the entire $63 million purchase price in cash.

Azenta, Inc. has appointed current Board member Dr. Martin Madaus as interim President and CEO following the resignation of John P. Marotta, while reaffirming Q4 FY2026 revenue guidance.

Azenta, Inc. announced the closing of the sale of its B Medical Systems business to Thelema S. r.l. for a fixed purchase price of $63 million.

Azenta, Inc. announced its second quarter fiscal year 2026 results, reporting revenue of $145 million, and revised its full-year guidance downwards due to a cautious demand environment and execution gaps.

Azenta, Inc. has appointed former Maravai LifeSciences CEO Trey Martin as President of its Multiomics business, succeeding Ginger Zhou.

Azenta, Inc. reported its Q2 2026 financial results, showing a slight revenue increase but a significant net loss driven by a $149.1 million goodwill impairment charge.

Azenta, Inc. reports a net loss of $15.4 million in Q1 2026, driven by a loss on assets held for sale, while advancing its strategic divestiture of the B Medical Systems business.

Azenta, Inc. reported a significant net loss for Q3 2025, primarily due to a substantial loss from discontinued operations, despite improvements in gross margin and reduced operating losses from continuing operations.

Azenta, Inc. announces a 5% increase in revenue for Q2 2025, driven by growth in Sample Management Solutions and Multiomics, while progressing with the planned sale of its B Medical Systems business.

Azenta's Q1 2025 shows revenue growth driven by Multiomics and Sample Management Solutions, alongside ongoing transformation efforts.

Azenta Inc. reported a net loss of $6.6 million for the third quarter of 2024, impacted by a significant goodwill impairment charge, despite a slight revenue increase.

Azenta, Inc. reported a net income from continuing operations of $24.5 million for fiscal year 2025, a significant improvement from a $24.4 million loss in the prior year, despite ongoing internal control weaknesses and a substantial loss from discontinued operations.

Azenta, Inc. reported a slight decrease in revenue for fiscal year 2024, alongside a significant net loss due to a goodwill impairment and increased operating expenses.

Martin D Madaus, Interim CEO of Azenta, Inc., received 36,653 shares of common stock on September 14, 2026.

William E. Martin Iii, President Multiomics of Azenta, Inc., received 15,272 shares of common stock on September 14, 2026.

Olga Pirogova, SVP and CHRO of Azenta, Inc., received 15,272 shares of common stock on September 14, 2026.

Lawrence Y. Lin, EVP, CFO and Treasurer of Azenta, Inc., received 30,544 shares of common stock on September 14, 2026.

Ephraim Starr, SVP, Gen Counsel & Secretary of Azenta, Inc., received 15,272 shares of common stock on September 14, 2026.

Erik J. Bello, VP Chief Accounting Officer of Azenta, Inc., received 4,586 shares of common stock on September 15, 2026.

Azenta, Inc. announces its 2026 Annual Meeting of Shareholders agenda, including the election of ten directors, an advisory vote on executive compensation, and a proposal to increase shares for its 2020 Equity Incentive Plan by 2,750,000.

Azenta, Inc. has filed definitive additional materials related to its proxy statement with the U.S. Securities and Exchange Commission.

Azenta, Inc. announces its Annual Meeting of Shareholders on January 28, 2026, to vote on director elections, executive compensation, an increase in equity plan shares, and auditor ratification.

Azenta, Inc. has filed its definitive proxy statement with the SEC, outlining proposals for the upcoming shareholder meeting.

Azenta, Inc. has released its proxy statement for the 2025 Annual Meeting of Stockholders, detailing director nominees, executive compensation, and other key proposals.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Azenta Inc. following an internal corporate realignment.

Dimensional Fund Advisors LP has reported a 4.6% beneficial ownership stake in Azenta Inc. common stock as of December 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 13.6% in Azenta, Inc.'s common stock, totaling 6,207,457 shares.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a passive beneficial ownership of 11.7% of Azenta, Inc.'s common stock as of March 31, 2025.